Alan Gabot, PharmD

Articles by Alan Gabot, PharmD

Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population

ByAlan Gabot, PharmD,Pavel Lavitas, PharmD, BCPS,Rachel Bacon, PharmD, MPH,Thomas C. Pomfret, PharmD, MPH, BCPS,Mckenzie Taylor, PharmD, MS,Andrew Coelho, PharmD,Bonnie C. Greenwood, PharmD, BCPS,Caroline J. Alper, MD,Karen M. Clements, ScD,Kimberly Lenz, PharmD, MBA

July 13th 2022

The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan.

Latest Updated Articles

Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population
Published: July 13th 2022 | Updated:

Alan Gabot, PharmD

Articles by Alan Gabot, PharmD

Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population

Latest Updated Articles

Trending on AJMC

Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies

Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD

Digital, Blood-Based Innovations Transform Alzheimer Disease Detection: Ken Cohen, MD, FACP

How Can Trauma Affect the Menopausal Transition?

FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause